The increasing need for purified, high-quality plasmid DNA for gene therapy, vaccine production, and molecular biology applications is driving market expansion. The ongoing adoption of innovative ...

Bharat Biotech launches Nucelion, the next-gen cell and gene therapy, CRDMO: Our Bureau, Bengaluru Monday, November 3, 2025, 17:30 Hrs [IST] Nucelion Therapeutics, a newly establi ...

Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene therapies. This new enti ...

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Hyderabad: Vaccine maker Bharat Biotech is foraying into the contract research development and manufacturing organisation ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

Bharat Biotech launches Nucelion Therapeutics, a CRDMO in Hyderabad for advanced cell and gene therapy manufacturing and development.